Announcement PDF Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040 ASX Announcement 21st September 2026 Atomo FY26 Results and Strategy Presentation Atomo Diagnostics Limited (ASX:AT1) is pleased to announce that Cheri Walker, new Chief Executive Officer, and Suzy Elhlou, Financial Controller, will host a webinar to provide an update on Atomo’s strategic direction and to discuss the FY26 financial results, on Thursday, 24 September 2026 at 11am (AEST). To access the webinar please pre-register via this link We encourage you to utilise our Investor Hub for any enquiries regarding this announcement. This platform offers an opportunity to submit questions and share comments. To access Atomo’s Investor Hub please scan the QR code or visit https://investors.atomodiagnostics.com/auth/signup ~ ENDS ~ For more information, please contact: Cheri Walker Executive Director & CEO e. cheri.walker@atomodiagnostics.com p. +61 2 9099 4750 Investor Queries investorqueries@atomodiagnostics.com This announcement was authorised by the CEO. About Atomo Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com